Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigecycline plus piperacillin/tazobactam in febrile neutropenia
ChiCTR-IPR-15006543Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tigecycline, piperacillin, tazobactam, imipenem and cilastatin in febrile neutropenia (FN) and bacterial disease (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Fever duration and Clinical treatment success rate. Planned start Jun 2015; status: not yet recruiting.
02
Drugs
03
Conditions
febrile neutropenia (FN)bacterial disease
Beyond the preview
Go deeper on ChiCTR-IPR-15006543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006543.